Aurdan Capital Management LLC Decreases Stake in Amgen Inc. $AMGN

Aurdan Capital Management LLC decreased its position in Amgen Inc. (NASDAQ:AMGN) by 22.6% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 16,901 shares of the medical research company’s stock after selling 4,937 shares during the period. Amgen accounts for 1.6% of Aurdan Capital Management LLC’s investment portfolio, making the stock its 16th biggest holding. Aurdan Capital Management LLC’s holdings in Amgen were worth $4,719,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. iA Global Asset Management Inc. increased its stake in Amgen by 4.6% in the 2nd quarter. iA Global Asset Management Inc. now owns 63,838 shares of the medical research company’s stock valued at $17,824,000 after buying an additional 2,821 shares during the last quarter. Mission Wealth Management LP increased its stake in shares of Amgen by 3.4% during the 2nd quarter. Mission Wealth Management LP now owns 11,370 shares of the medical research company’s stock worth $3,175,000 after purchasing an additional 379 shares during the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors increased its stake in shares of Amgen by 6.4% during the 2nd quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors now owns 1,354 shares of the medical research company’s stock worth $378,000 after purchasing an additional 82 shares during the last quarter. Welch & Forbes LLC increased its stake in shares of Amgen by 1.2% during the 2nd quarter. Welch & Forbes LLC now owns 25,434 shares of the medical research company’s stock worth $7,101,000 after purchasing an additional 309 shares during the last quarter. Finally, GHP Investment Advisors Inc. increased its stake in shares of Amgen by 0.6% during the 2nd quarter. GHP Investment Advisors Inc. now owns 27,495 shares of the medical research company’s stock worth $7,677,000 after purchasing an additional 151 shares during the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Stock Up 2.2%

AMGN opened at $298.43 on Friday. The company has a 50 day moving average of $287.75 and a 200 day moving average of $287.46. The company has a market cap of $160.66 billion, a PE ratio of 24.40, a price-to-earnings-growth ratio of 2.61 and a beta of 0.49. Amgen Inc. has a 12 month low of $253.30 and a 12 month high of $335.88. The company has a current ratio of 1.31, a quick ratio of 0.98 and a debt-to-equity ratio of 7.24.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, August 5th. The medical research company reported $6.02 EPS for the quarter, topping the consensus estimate of $5.28 by $0.74. The company had revenue of $9.18 billion during the quarter, compared to the consensus estimate of $8.86 billion. Amgen had a net margin of 18.96% and a return on equity of 174.71%. Amgen’s revenue for the quarter was up 9.4% on a year-over-year basis. During the same period last year, the firm earned $4.97 EPS. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. On average, sell-side analysts expect that Amgen Inc. will post 20.62 EPS for the current year.

Insider Buying and Selling

In related news, SVP Nancy A. Grygiel sold 1,267 shares of the firm’s stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $296.99, for a total value of $376,286.33. Following the completion of the transaction, the senior vice president directly owned 7,209 shares of the company’s stock, valued at approximately $2,141,000.91. This trade represents a 14.95% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.76% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on AMGN shares. Piper Sandler raised their price target on shares of Amgen from $328.00 to $342.00 and gave the stock an “overweight” rating in a research note on Monday, August 25th. Morgan Stanley raised their price target on shares of Amgen from $330.00 to $333.00 and gave the stock an “equal weight” rating in a research note on Wednesday, August 6th. Bank of America raised their price target on shares of Amgen from $261.00 to $272.00 and gave the stock an “underperform” rating in a research note on Friday, September 26th. Citigroup raised their price target on shares of Amgen from $310.00 to $315.00 and gave the stock a “neutral” rating in a research note on Wednesday, September 24th. Finally, UBS Group decreased their price target on shares of Amgen from $326.00 to $317.00 and set a “neutral” rating for the company in a research note on Wednesday, August 6th. Six equities research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $300.94.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.